Secondary Logo

Institutional members access full text with Ovid®

Evolution of Endoscopic Bariatric Devices

From Development to Practice

Goyal, Deepinder, MD1; Singh, Vikesh K., MD, MSC2; Amateau, Stuart K., MD, PhD3 the FDA-Related Matters Committee of the American College of Gastroenterology

American Journal of Gastroenterology: April 2019 - Volume 114 - Issue 4 - p 679–683
doi: 10.14309/ajg.0000000000000134

OBJECTIVES: To familiarize medical providers with the Food and Drug Administration approval process for antiobesity devices and to provide a brief overview of current and promising endoscopy-based bariatric devices.

METHODS: Literature review of published scholarly articles.

RESULTS: There has been a rapid development of novel endoscopic bariatric therapies in recent years, resulting in the approval of multiple devices. Several promising endoscopic strategies are currently under investigation and review. The Food and Drug Administration has laid down an objective-tiered model to review antiobesity device applications.

DISCUSSION: Endoscopic bariatric devices provide a new and promising paradigm in obesity management both as first-line therapy and as adjunctive treatment to medical and surgical strategies. Physicians who plan to offer endoscopic bariatric therapy in their practice need appropriate understanding of the regulatory processes involved in the development and approval of such devices.

1Division of Digestive Disease, University of California Los Angeles Health, Los Angeles, California, USA;

2Division of Gastroenterology and Hepatology, The Johns Hopkins Hospital, Baltimore, Maryland, USA;

3Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota, USA.

Received July 13, 2018

Accepted December 18, 2018

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website